Navigation Links
Static killers?
Date:9/6/2013

Since its discovery in the early 1990s, the protein STAT1 (Signal Transducer and Activator of Transcription 1) has been found to be central in passing signals across immune cells, ensuring that our bodies react quickly and appropriately to threats from viruses or other pathogens. Animals without STAT1 are also prone to develop cancer, suggesting that STAT1 is somehow involved in protection against malignant cells. The STAT1 protein is known to be phosphorylated on at least two positions: phosphorylation of a particular tyrosine (tyr-701) is required for the protein to enter the cell nucleus (where it exerts its effects), while subsequent phosphorylation of a serine residue alters the way it interacts with other proteins, thereby affecting its function.

Natural Killer (NK) cells are among the first cells to respond to infections by viruses or to attack malignant cells when tumours develop. When they detect cells to be targeted, they produce a number of proteins, such as granzyme B and perforin, that enter infected cells and destroy them from within. Clearly, the lethal activity must be tightly controlled to prevent NK cells from running wild and destroying healthy cells or tissues. How is this done?

Eva Maria Putz and colleagues at the Institute of Pharmacology and Toxicology of the University of Veterinary Medicine, Vienna (Vetmeduni) have now investigated the importance of STAT1 phosphorylation in NK cells. The researchers found that when a particular serine residue (ser-727) in the STAT1 protein is mutated, NK cells produce far higher amounts of granzyme B and perforin and are far more effective at killing a wide range of tumour cells. Mice with the correspondingly mutated Stat1 gene are far less likely to develop melanoma, leukaemia or metastasizing breast cancer. On the other hand, when the same serine residue is phosphorylated, the NK cells are less able to kill infected or cancerous cells.

The Vetmeduni researchers have accumulated a body of evidence to suggest that the cyclin-dependent kinase CDK8 phosphorylates STAT1 on serine 727. Surprisingly, this phosphorylation does not require prior phosphorylation of the activating tyrosine residue, at least in NK cells. Instead, it seems to represent a way in which the lethal activity of the NK cells is kept in check. Putz is keen to note the potential significance of the finding. As she says, "If we can stop CDK8 from inactivating STAT1 in NK cells, we could stimulate tumour surveillance and thus possibly have a new handle on treating cancer, harnessing the body's own weapons against malignant cells."


'/>"/>

Contact: Susanna Kautschitsch
susanna.kautschitsch@vetmeduni.ac.at
43-125-077-1153
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Related biology news :

1. Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
2. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
3. Modulating the immune system to combat metastatic cancer
4. LSUHSC research discovers new drug target for metastatic breast cancer
5. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
6. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
7. 3dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging
8. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
9. Cancerous tumors deliver pro-metastatic information in secreted vesicles
10. Mechanism found connecting metastatic breast cancer and arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 ... is one of the most crucial aspects of recovery so we need to do ... serious health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... friends sleep and find a Christmas present that could help them to manage their ... ...
(Date:11/29/2016)... 2016 Nearly one billion matches per second with ... ... DERMALOG is Germany's largest ... Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... fiscal year ended September 30, 2016. ... , , SQI ... company that develops and commercializes proprietary technologies and products for advanced ... revenues of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Superior Controls, ... solutions, today announced the company has successfully completed its 50th consecutive audit. ... control systems integration services to leading companies in life sciences, food and beverage, ...
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... development of precision treatments for neurodegenerative diseases, today announced the validated monoclonal ... the direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology: